Becton, Dickinson and Company (BDX)

In the past six months, Becton, Dickinson & Co.'s stock price declined by 13.23% between January 10, 2025, and January 9, 2026. In December 2025, BD launched the global commercialization of new cell analyzer configurations and expanded its diagnostic offerings in Europe with new VIASURE assays for the BD MAX System and announced a partnership with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. In November 2025, BD announced an increase in its dividend to $1.05 per share. In October 2025, the company announced a CFO transition plan. BD is investing $110 million to boost prefillable syringe production in Columbus, Nebraska.

While specific demand seasonality for Becton, Dickinson & Co.'s individual products and services is not explicitly detailed, the broader medical device industry can experience seasonal trends influenced by annual festivals, holidays, and healthcare awareness days. Demand forecasting in healthcare is aided by analyzing purchasing history and seasonality. External macro factors like public health data and disease outbreaks can also influence demand for medical devices. The medical device market generally benefits from consistent demand and recurring revenue from consumables.

Becton, Dickinson and Company (BDX), also known as BD, is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. The company operates within the Health Care sector, specifically in the Health Care Equipment & Supplies industry, and is structured around three primary segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on medication management and delivery technologies. BD Life Sciences is dedicated to diagnostic systems and research tools. BD Interventional provides single-use or implantable devices for vascular, surgical, and urological applications. BD's products serve healthcare institutions, physicians, life science researchers, clinical laboratories, and pharmaceutical companies worldwide.

BD has a significant global presence, operating in over 190 countries and employing more than 70,000 people. The company maintains manufacturing facilities across North America, Europe, and Asia, including in the United States, Canada, Brazil, the Dominican Republic, France, Germany, Hungary, India, Japan, and Mexico. BD's European headquarters opened in Meylan, France, in 1975, and a manufacturing facility in Singapore was established in 1987. International revenue accounts for 43% of the company's business.

BD has received positive recognition for its brand reputation in the past year. In September 2024, BD was named to TIME's 2024 list of the World's Best Companies. In October 2024, 3BL recognized BD as one of the 100 Best Corporate Citizens of 2024, ranking second in the health care equipment and services industry. In March 2025, BD was included in Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% overall.

Becton, Dickinson & Co.'s ownership is predominantly institutional, with institutional investors holding over 86% to 90% of the stock. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., T. Rowe Price Investment Management, Inc., and State Street Corp. Vanguard Group Inc is the largest individual institutional shareholder, owning approximately 11.37% of the company's shares. Individual investors and other public entities hold around 12% to 22.89% of the company. Insiders own less than 1% of the company's shares.